Our findings also suggest that modulating SRPK1 levels to affect splicing factor activity and subsequent translation of mRNAs and expression of genes associated with growth control provides an opportunity to treat the abnormal growth of ovarian cancer cells. The gene discussed is SRPK1; the disease is ovarian carcinoma.